SCHEMBL6776064

SCHEMBL6776064

N=C(N)Nc1cccc(C(=O)NCC(=O)NC(CC(=O)O)c2ccsc2)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 13/20 0.46
ITGAV P06756 9/20 0.46
ITGB1 P05556 7/20 0.46
ITGA5 P08648 7/20 0.46
ITGB6 P18564 5/20 0.46
ITGB5 P18084 3/20 0.46
ITGB8 P26012 3/20 0.46
ITGA8 P53708 3/20 0.46
ITGA2B P08514 4/20 0.45
MDM4 O15151 3/20 0.41
MDM2 Q00987 3/20 0.41
GPR139 Q6DWJ6 5/20 0.41
SLC6A9 P48067 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7341564 0.90 GPR139 (0.41) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL242674 0.88 ITGB3 (0.55) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL7343500 0.86 ITGB3 (0.45) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6778587 0.86 ITGB3 (0.49) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6779336 0.85 ITGB3 (0.49) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL244261 0.85 ITGB3 (0.50) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6776866 0.85 ITGB3 (0.53) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6779560 0.85 ITGB3 (0.50) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6779116 0.85 ITGB3 (0.51) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6773834 0.85 ITGB3 (0.51) ITGB3ITGAVITGB1ITGA5ITGB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed